Buzzard Pharmaceuticals AB

Buzzard Pharmaceuticals is a small privately held oncology development company. Management has track record of successfull company development with the predecessor Cormorant Pharmaceuticals that was sold to BMS in 2016. We are developing a potent IL-1 inhibitor (isunakinra) to be used to improve efficacy of immunotherapies and alleviate side effects. We recently completed a phase I dose escalation study in solid tumor patients in combination with a PD-1 inhibitor at Baylor. The study results are promising and we have great incoming interest from leading US cancer institutions to follow up in different tumor settings.